Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Mice lacking major brain gangliosides develop parkinsonism.

Wu G, Lu ZH, Kulkarni N, Amin R, Ledeen RW.

Neurochem Res. 2011 Sep;36(9):1706-14. doi: 10.1007/s11064-011-0437-y. Epub 2011 Mar 12.

2.

Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.

Wu G, Lu ZH, Kulkarni N, Ledeen RW.

J Neurosci Res. 2012 Oct;90(10):1997-2008. doi: 10.1002/jnr.23090. Epub 2012 Jun 20.

PMID:
22714832
4.

A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.

Szego ÉM, Gerhardt E, Kermer P, Schulz JB.

Neurobiol Dis. 2012 Jan;45(1):591-600. doi: 10.1016/j.nbd.2011.09.017. Epub 2011 Oct 7.

PMID:
22001606
5.

Gangliosides, α-Synuclein, and Parkinson's Disease.

Ledeen RW, Wu G.

Prog Mol Biol Transl Sci. 2018;156:435-454. doi: 10.1016/bs.pmbts.2017.12.009. Epub 2018 Feb 24.

PMID:
29747823
6.

Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.

Heng Y, Zhang QS, Mu Z, Hu JF, Yuan YH, Chen NH.

Toxicol Lett. 2016 Jan 22;243:7-21. doi: 10.1016/j.toxlet.2015.12.005. Epub 2015 Dec 23.

PMID:
26723869
7.

α-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2.

Kett LR, Stiller B, Bernath MM, Tasset I, Blesa J, Jackson-Lewis V, Chan RB, Zhou B, Di Paolo G, Przedborski S, Cuervo AM, Dauer WT.

J Neurosci. 2015 Apr 8;35(14):5724-42. doi: 10.1523/JNEUROSCI.0632-14.2015.

8.

Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.

Liu Y, Sun JD, Song LK, Li J, Chu SF, Yuan YH, Chen NH.

Behav Brain Res. 2015 Nov 1;294:149-61. doi: 10.1016/j.bbr.2015.07.058. Epub 2015 Jul 31.

PMID:
26239001
9.

Changes in cytokines and neurotrophins in Parkinson's disease.

Nagatsu T, Mogi M, Ichinose H, Togari A.

J Neural Transm Suppl. 2000;(60):277-90. Review.

PMID:
11205147
10.

Brain region-dependent differential expression of alpha-synuclein.

Taguchi K, Watanabe Y, Tsujimura A, Tanaka M.

J Comp Neurol. 2016 Apr 15;524(6):1236-58. doi: 10.1002/cne.23901. Epub 2015 Sep 29.

PMID:
26358191
11.

Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.

Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Wada K, Hattori N, Mizuno Y, Mochizuki H.

J Neurochem. 2009 Feb;108(4):932-44. doi: 10.1111/j.1471-4159.2008.05827.x. Epub 2009 Jan 7.

12.

Imaging mass spectrometry detection of gangliosides species in the mouse brain following transient focal cerebral ischemia and long-term recovery.

Whitehead SN, Chan KH, Gangaraju S, Slinn J, Li J, Hou ST.

PLoS One. 2011;6(6):e20808. doi: 10.1371/journal.pone.0020808. Epub 2011 Jun 8.

13.

Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease.

Ebadi M, Brown-Borg H, El Refaey H, Singh BB, Garrett S, Shavali S, Sharma SK.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):67-75. Review.

14.

Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.

Sathiya S, Ranju V, Kalaivani P, Priya RJ, Sumathy H, Sunil AG, Babu CS.

Neuropharmacology. 2013 Oct;73:98-110. doi: 10.1016/j.neuropharm.2013.05.025. Epub 2013 Jun 6.

PMID:
23747572
15.

Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.

Caudal D, Alvarsson A, Björklund A, Svenningsson P.

Exp Neurol. 2015 Nov;273:243-52. doi: 10.1016/j.expneurol.2015.09.002. Epub 2015 Sep 9.

PMID:
26363495
16.
17.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

PMID:
19903734
18.

Myelin-associated glycoprotein (Siglec-4) expression is progressively and selectively decreased in the brains of mice lacking complex gangliosides.

Sun J, Shaper NL, Itonori S, Heffer-Lauc M, Sheikh KA, Schnaar RL.

Glycobiology. 2004 Sep;14(9):851-7. Epub 2004 Jun 2.

PMID:
15175257
19.

Dopamine and α-synuclein dysfunction in Smad3 null mice.

Tapia-González S, Giráldez-Pérez RM, Cuartero MI, Casarejos MJ, Mena MÁ, Wang XF, Sánchez-Capelo A.

Mol Neurodegener. 2011 Oct 13;6:72. doi: 10.1186/1750-1326-6-72.

20.

Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.

Peneder TM, Scholze P, Berger ML, Reither H, Heinze G, Bertl J, Bauer J, Richfield EK, Hornykiewicz O, Pifl C.

Neuroscience. 2011 Apr 28;180:280-92. doi: 10.1016/j.neuroscience.2011.02.017. Epub 2011 Feb 16.

PMID:
21333719

Supplemental Content

Support Center